株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

肝性脳症(HE) - 市場洞察、疫学、市場予測 2028年

Hepatic Encephalopathy - Market Insights, Epidemiology, and Market Forecast - 2028

発行 DelveInsight Business Research LLP 商品コード 534759
出版日 ページ情報 英文 160 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=109.06円で換算しております。
Back to Top
肝性脳症(HE) - 市場洞察、疫学、市場予測 2028年 Hepatic Encephalopathy - Market Insights, Epidemiology, and Market Forecast - 2028
出版日: 2019年09月01日 ページ情報: 英文 160 Pages
概要

主要7カ国(米国、英国、ドイツ、フランス、イタリア、スペイン、日本)の肝性脳症(HE)の有病数は、2017年に約35万米ドル8,910人、その市場規模は9億1,000万米ドルと推計されています。

当レポートでは、主要7カ国(米国、英国、ドイツ、フランス、イタリア、スペイン、日本)の肝性脳症(HE)市場を調査し、市場および疾患の概要、国別の市場規模、性別・年齢・タイプ別の有病数の推移と予測(通算12年間分)、現行の治療法、上市済み治療薬および新薬の概要、市場の成長要因および障壁、などについてまとめています。

目次

第1章 重要洞察

第2章 肝性脳症(HE)市場の概要

  • 市場シェアと分布状況(実績値)
  • 市場シェアと分布状況(予測値)

第3章 肝性脳症(HE):疾患の背景と概要

  • イントロダクション
  • 分類
  • 症状
  • 危険因子
  • 病態生理
  • 病因
  • 診断
  • 鑑別診断
  • 肝性脳症 2018年:イタリア肝臓研究協会(AISF)の臨床診療ガイドライン

第4章 疫学と患者人口

  • 主な調査結果
  • 調査手法
  • 主要7カ国の肝性脳症(HE)の総有病数
  • 主要7カ国の肝性脳症(HE)の総診断有病数

第5章 肝性脳症の疫学:国別

  • 米国の疫学
    • 仮定と根拠
    • 総有病数
    • 総診断有病数
    • 有病数:性別
    • 有病数:年齢別
    • 有病数:タイプ別
  • 欧州5カ国の疫学
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • 英国

第6章 日本の疫学

  • 仮定と根拠
  • 総有病数
  • 総診断有病数
  • 有病数:性別
  • 有病数:年齢別
  • 有病数:タイプ別

第7章 肝性脳症(HE)の治療と管理

  • 肝性脳症の一連の治療
  • 治療アルゴリズム
  • 治療ガイドライン

第8章 アンメットニーズ

第9章 上市済み治療薬

  • Xifaxan:Salix Pharmaceuticals
    • 製品説明
    • 規制のマイルストーン
    • 研究開発
    • 臨床試験情報
    • 製品プロファイル

第10章 新薬

  • キークロスコンペティション
  • SYNB1020:Synlogic
    • 製品説明
    • その他の開発動向
    • 臨床開発
    • 臨床試験情報
    • 製品プロファイル
  • GR3027:Umecrine Cognition
    • 安全性と有効性
  • MNK-6105 / MNK-6106:Mallinckrodt Therapeutics

第11章 肝性脳症(HE):主要7カ国市場の分析

  • 主な調査結果
  • 主要7カ国の総市場規模
  • 主要7カ国の市場規模:治療薬別

第12章 市場の見通し:米国

  • 米国の市場規模
    • 主要7カ国の総市場規模
    • 主要7カ国の市場規模:現行治療薬・新薬別

第13章 市場の見通し:欧州5カ国

  • ドイツ
    • 総市場規模
    • 市場規模:現行治療薬・新薬別
  • フランス
    • 総市場規模
    • 市場規模:現行治療薬・新薬別
  • イタリア
    • 総市場規模
    • 市場規模:現行治療薬・新薬別
  • スペイン
    • 総市場規模
    • 市場規模:現行治療薬・新薬別
  • 英国

第14章 市場の見通し:日本

  • 総市場規模
  • 市場規模:現行治療薬・新薬別

第15章 市場の成長要因

第16章 市場の障壁

章17:付録

  • 調査手法

第18章 DelveInsightのサービス内容

第19章 免責事項

第20章 DelveInsightについて

図表

List of Tables

  • Table 1 Clinical Description of Hepatic Encephalopathy (Adapted from AASLD-EASL Guideline 2014
  • Table 2 West Haven Criteria for hepatic encephalopathy and symptoms
  • Table 3 Stages of Hepatic Encephalopathy (HE)
  • Table 4 Total Prevalent Patient Population of Hepatic Encephalopathy in 7MM (2017-2028)
  • Table 5 Total Diagnosed Prevalent Patient Population of Hepatic Encephalopathy in 7MM (2017-2028)
  • Table 6 Total Prevalent Population of Hepatic Encephalopathy in the United States (2017-2028)
  • Table 7 Total Diagnosed Prevalent Population of Hepatic Encephalopathy in the United States (2017-2028)
  • Table 8 Gender-Specific Diagnosed Prevalence of Hepatic Encephalopathy in the United States (2017-2028)
  • Table 9 Age-Specific Diagnosed Prevalence of Hepatic Encephalopathy in the United States (2017-2028)
  • Table 10 Type-Specific Diagnosed Prevalence of Hepatic Encephalopathy in the United States (2017-2028)
  • Table 11 Total Prevalent Population of Hepatic Encephalopathy in Germany (2017-2028)
  • Table 12 Total Diagnosed Prevalent Population of Hepatic Encephalopathy in Germany (2017-2028)
  • Table 13 Gender-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Germany (2017-2028)
  • Table 14 Age-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Germany (2017-2028)
  • Table 15 Type-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Germany (2017-2028)
  • Table 16 Total Prevalent Population of Hepatic Encephalopathy in France (2017-2028)
  • Table 17 Total Diagnosed Prevalent Population of Hepatic Encephalopathy in France (2017-2028)
  • Table 18 Gender-Specific Diagnosed Prevalence of Hepatic Encephalopathy in France (2017-2028)
  • Table 19 Age-Specific Diagnosed Prevalence of Hepatic Encephalopathy in France (2017-2028)
  • Table 20 Type-Specific Diagnosed Prevalence of Hepatic Encephalopathy in France (2017-2028)
  • Table 21 Total Prevalent Population of Hepatic Encephalopathy in Italy (2017-2028)
  • Table 22 Total Diagnosed Prevalent Population of Hepatic Encephalopathy in Italy (2017-2028)
  • Table 23 Gender-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Italy (2017-2028)
  • Table 24 Age-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Italy (2017-2028)
  • Table 25 Type-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Italy (2017-2028)
  • Table 26 Total Prevalent Population of Hepatic Encephalopathy in Spain (2017-2028)
  • Table 27 Total Diagnosed Prevalent Population of Hepatic Encephalopathy in Spain (2017-2028)
  • Table 28 Gender-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Spain (2017-2028)
  • Table 29 Age-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Spain (2017-2028)
  • Table 30 Type-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Spain (2017-2028)
  • Table 31 Total Prevalent Population of Hepatic Encephalopathy in the United Kingdom (2017-2028)
  • Table 32 Total Diagnosed Prevalent Population of Hepatic Encephalopathy in the United Kingdom (2017-2028)
  • Table 33 Gender-Specific Diagnosed Prevalence of Hepatic Encephalopathy in the United Kingdom (2017-2028)
  • Table 34 Age-Specific Diagnosed Prevalence of Hepatic Encephalopathy in the United Kingdom (2017-2028)
  • Table 35 Type-Specific Diagnosed Prevalence of Hepatic Encephalopathy in the United Kingdom (2017-2028)
  • Table 36 Total Prevalent Population of Hepatic Encephalopathy in Japan (2017-2028)
  • Table 37 Total Diagnosed Prevalent Population of Hepatic Encephalopathy in Japan (2017-2028)
  • Table 38 Gender-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Japan (2017-2028)
  • Table 39 Age-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Japan (2017-2028)
  • Table 40 Type-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Japan (2017-2028)
  • Table 41 Common Treatment Options for Hepatic Encephalopathy
  • Table 42 Treatment Summary
  • Table 43 Rifaximin, Clinical Trial Description, 2019
  • Table 44 List of Few Emerging Drugs Analysis
  • Table 45 SYNB1020, Clinical Trial Description, 2019
  • Table 46 MNK6106, Clinical Trial Description, 2019
  • Table 47 Market size of Hepatic Encephalopathy by Region in USD Million (2017-2028)
  • Table 48 Market Size of Hepatic Encephalopathy by Current Treatment and Emerging Therapy in 7MM, in USD Million (2017-2028)
  • Table 49 United States Market Size of Hepatic Encephalopathy in USD Million (2017-2028)
  • Table 50 The US Market Size of Hepatic Encephalopathy by Current Treatment and Emerging Therapy in USD Million (2017-2028)
  • Table 51 Germany Market Size of Hepatic Encephalopathy in USD Million (2017-2028)
  • Table 52 Germany Market Size of HE by Current Treatment and Emerging Therapy in USD Million (2017-2028)
  • Table 53 France Market Size of Hepatic Encephalopathy in USD Million (2017-2028)
  • Table 54 France Market Size of HE by Current Treatment and Emerging Therapy in USD Million (2017-2028)
  • Table 55 Italy Market Size of Hepatic Encephalopathy in USD Million (2017-2028)
  • Table 56 Italy Market Size of HE by Current Treatment and Emerging Therapy in USD Million (2017-2028)
  • Table 57 Spain Market Size of Hepatic Encephalopathy in USD Million (2017-2028)
  • Table 58 Spain Market Size of HE by Current Treatment and Emerging Therapy in USD Million (2017-2028)
  • Table 59 United Kingdom Market Size of Hepatic Encephalopathy in USD Million (2017-2028)
  • Table 60 The UK Market Size of HE by Current Treatment and Emerging Therapy in USD Million (2017-2028)
  • Table 61 Japan Market Size of Hepatic Encephalopathy in USD Million (2017-2028)
  • Table 62 Japan Market Size of HE by Current Treatment and Emerging Therapy in USD Million (2017-2028)

List of Figures

  • Figure 1 Symptoms of Hepatic Encephalopathy
  • Figure 2 Grading of the symptoms of Hepatic Encephalopathy
  • Figure 3 Symptoms of Hepatic Encephalopathy
  • Figure 4 Pathophysiology of hepatic encephalopathy
  • Figure 5 Pathophysiology of hepatic encephalopathy
  • Figure 6 Ammonia trafficking in hepatic encephalopathy (HE) from an organism (left panel) and an organ (right panel) perspective
  • Figure 7 The classification of HE, adapted from Amodio et al.
  • Figure 8 Total Prevalent Cases of Hepatic Encephalopathy in the 7MM (2017-2028)
  • Figure 9 Total Diagnosed Prevalent Cases of Hepatic Encephalopathy in the 7MM (2017-2028)
  • Figure 10 Total Prevalent Cases of Hepatic Encephalopathy in the United States (2017-2028)
  • Figure 11 Total Diagnosed Prevalent Cases of Hepatic Encephalopathy in the United States (2017-2028)
  • Figure 12 Gender-Specific Diagnosed Prevalence of Hepatic Encephalopathy in the United States (2017-2028)
  • Figure 13 Age-Specific Diagnosed Prevalence of Hepatic Encephalopathy in the United States (2017-2028)
  • Figure 14 Type-Specific Diagnosed Prevalence of Hepatic Encephalopathy in the United States (2017-2028)
  • Figure 15 Total Prevalent Cases of Hepatic Encephalopathy in Germany (2017-2028)
  • Figure 16 Total Diagnosed Prevalent Cases of Hepatic Encephalopathy in Germany (2017-2028)
  • Figure 17 Gender-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Germany (2017-2028)
  • Figure 18 Age-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Germany (2017-2028)
  • Figure 19 Type-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Germany (2017-2028)
  • Figure 20 Total Prevalent Cases of Hepatic Encephalopathy in France (2017-2028)
  • Figure 21 Total Diagnosed Prevalent Cases of Hepatic Encephalopathy in France (2017-2028)
  • Figure 22 Gender-Specific Diagnosed Prevalence of Hepatic Encephalopathy in France (2017-2028)
  • Figure 23 Age-Specific Diagnosed Prevalence of Hepatic Encephalopathy in France (2017-2028)
  • Figure 24 Type-Specific Diagnosed Prevalence of Hepatic Encephalopathy in France (2017-2028)
  • Figure 25 Total Prevalent Cases of Hepatic Encephalopathy in Italy (2017-2028)
  • Figure 26 Total Diagnosed Prevalent Cases of Hepatic Encephalopathy in Italy (2017-2028)
  • Figure 27 Gender-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Italy (2017-2028)
  • Figure 28 Age-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Italy (2017-2028)
  • Figure 29 Type-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Italy (2017-2028)
  • Figure 30 Total Prevalent Cases of Hepatic Encephalopathy in Spain (2017-2028)
  • Figure 31 Total Diagnosed Prevalent Cases of Hepatic Encephalopathy in Spain (2017-2028)
  • Figure 32 Gender-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Spain (2017-2028)
  • Figure 33 Age-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Spain (2017-2028)
  • Figure 34 Type-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Spain (2017-2028)
  • Figure 35 Total Prevalent Cases of Hepatic Encephalopathy in the United Kingdom (2017-2028)
  • Figure 36 Total Diagnosed Prevalent Cases of Hepatic Encephalopathy in the United Kingdom (2017-2028)
  • Figure 37 Gender-Specific Diagnosed Prevalence of Hepatic Encephalopathy in the United Kingdom (2017-2028)
  • Figure 38 Age-Specific Diagnosed Prevalence of Hepatic Encephalopathy in the United Kingdom (2017-2028)
  • Figure 39 Type-Specific Diagnosed Prevalence of Hepatic Encephalopathy in the United Kingdom (2017-2028)
  • Figure 40 Total Prevalent Cases of Hepatic Encephalopathy in Japan (2017-2028)
  • Figure 41 Total Diagnosed Prevalent Cases of Hepatic Encephalopathy in Japan (2017-2028)
  • Figure 42 Gender-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Japan (2017-2028)
  • Figure 43 Age-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Japan (2017-2028)
  • Figure 44 Type-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Japan (2017-2028)
  • Figure 45 Management of patients with hepatic encephalopathy (HE)
  • Figure 46 Treatment algorithm for patients with minimal HE
  • Figure 47 Treatment algorithm for patients with minimal HE
  • Figure 48 Practice Guideline on Hepatic Encephalopathy from the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver
  • Figure 49 Unmet Needs
  • Figure 50 Market size of Hepatic Encephalopathy by Region in USD Million (2017-2028)
  • Figure 51 Market Size of Hepatic Encephalopathy by Therapies in the Seven Major Market (7MM), in USD Million (2017-2028)
  • Figure 52 United States Market Size of Hepatic Encephalopathy in USD Million (2017-2028)
  • Figure 53 The US Market Size of Hepatic Encephalopathy by Current Treatment and Emerging Therapy in USD Million (2017-2028)
  • Figure 54 Germany Market Size of Hepatic Encephalopathy in USD Million (2017-2028)
  • Figure 55 Germany Market Size of Hepatic Encephalopathy by Current Treatment and Emerging Therapy in USD Million (2017-2028)
  • Figure 56 France Market Size of Hepatic Encephalopathy in USD Million (2017-2028)
  • Figure 57 France Market Size of Hepatic Encephalopathy by Current Treatment and Emerging Therapy in USD Million (2017-2028)
  • Figure 58 Italy Market Size of Hepatic Encephalopathy in USD Million (2017-2028)
  • Figure 59 Italy Market Size of Hepatic Encephalopathy by Current Treatment and Emerging Therapy in USD Million (2017-2028)
  • Figure 60 Spain Market Size of Hepatic Encephalopathy in USD Million (2017-2028)
  • Figure 61 Spain Market Size of Hepatic Encephalopathy by Current Treatment and Emerging Therapy in USD Million (2017-2028)
  • Figure 62 United Kingdom Market Size of Hepatic Encephalopathy in USD Million (2017-2028)
  • Figure 63 The UK Market Size of Hepatic Encephalopathy by Current Treatment and Emerging Therapy in USD Million (2017-2028)
  • Figure 64 Japan Market Size of Hepatic Encephalopathy in USD Million (2017-2028)
  • Figure 65 Japan Market Size of Hepatic Encephalopathy by Current Treatment and Emerging Therapy in USD Million (2017-2028)
  • Figure 66 Market Drivers
  • Figure 67 Market Barriers
目次
Product Code: DIMI0099

DelveInsight's 'Hepatic Encephalopathy- Market Insights, Epidemiology, and Market Forecast-2028' report deliver an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Hepatic Encephalopathy in the United States, EU5 (Germany, Spain, Italy, France and the United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, the current and forecasted market size of Hepatic Encephalopathy from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2028

Hepatic Encephalopathy - Disease Understanding and Treatment Algorithm

The DelveInsight Hepatic Encephalopathy market report gives a thorough understanding of the Hepatic Encephalopathy by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Hepatic Encephalopathy in the US, Europe, and Japan.

Hepatic Encephalopathy

The Hepatic Encephalopathy epidemiology division provide insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Prevalence of Hepatic Encephalopathy in 7MM, Total Diagnosed Prevalence of Hepatic Encephalopathy in 7MM, Gender-specific Diagnosed Prevalence of Hepatic Encephalopathy, Age-specific Diagnosed Prevalence of Hepatic Encephalopathy, and Type Specific Diagnosed Prevalence of Hepatic Encephalopathy) scenario of Hepatic Encephalopathy in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028.

According to DelveInsight, the total number of diagnosed prevalent population of Hepatic Encephalopathy in 7MM was found to be approximately 358,910 in the year 2017.

Hepatic Encephalopathy Drug Chapters

This segment of the Hepatic Encephalopathy report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Management of overt HE includes treating patients with acute HE episodes, preventing HE recurrence, and identifying and managing precipitating factors associated with the development of HE. The two main forms of medical therapy for HE are non-absorbable disaccharides (i.e., lactitol and lactulose) and non-absorbable antibiotics (i.e. rifaximin). The hyperammonemia and inflammation that occurs due to urea breakdown in cirrhotics have led to the development of HE treatments that target gut bacteria. Treatments for OHE approved by the US Food and Drug Administration (FDA), as well as some unapproved treatments, are available for use. It is important to remember that in patients with cirrhosis and portosystemic shunting, skeletal muscle mass and renal clearance are vital to neurotoxin clearance. Nutrition may also play a key role in managing HE and preventing a recurrence. The second line, less accepted therapies, include probiotics, branched-chain amino acids (BCAAs), flumazenil, zinc, and ammonia scavengers.

The first-line agent used to prevent acute or persistent HE is the nonabsorbable disaccharides (lactulose or lactitol). Clinical trials have established the efficacy of the nonabsorbable disaccharides in enema form to treat acute episodes of HE. Nonabsorbable disaccharides, lactulose, and lactitol (not used in the United States) have long been the mainstay of treatment for HE.

The second-line agents include oral antibiotics (neomycin, metronidazole, and rifaximin) that can reduce urease-producing bacteria in the intestines, resulting in a decrease of ammonia production and absorption through the gastrointestinal tract. The current guidelines recommend the addition of rifaximin to lactulose for the prevention of HE recurrence after the second episode of HE.

The third-line agents available for patients who cannot tolerate the above agents or still have persistent or episodic HE on the above agents are sodium benzoate, zinc, or bromocriptine. In addition, patients with unique situations may also benefit from an agent in this class.

There is only one drug that is going to be launched in 2023 which will contribute to an increase in the market size of Hepatic Encephalopathy. Mallinckrodt Therapeutics is developing MNK-6105/MNK-6106 for treatment and prevention of Hepatic encephalopathy.

Hepatic Encephalopathy Market Outlook

The Hepatic Encephalopathy market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the market of Hepatic Encephalopathy in 7MM was found to be approximately USD 910.0 million in 2017 and is expected to increase from 2017-2028.

Hepatic Encephalopathy Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Hepatic Encephalopathy Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Hepatic Encephalopathy Report Key Strengths

  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Hepatic Encephalopathy Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Hepatic Encephalopathy Infections market
  • Organize sales and marketing efforts by identifying the best opportunities for Hepatic Encephalopathy market
  • To understand the future market competition in the Hepatic Encephalopathy market.

Table of Contents

1. Key Insights

2. Hepatic Encephalopathy Market Overview at a Glance

  • 2.1. Market Share (%) Distribution of Hepatic Encephalopathy (HE) in 2017
  • 2.2. Market Share (%) Distribution of Hepatic Encephalopathy (HE) in 2028

3. Hepatic Encephalopathy (HE): Disease Background and Overview

  • 3.1. Introduction
  • 3.2. Classification of Hepatic Encephalopathy
  • 3.3. Symptoms of Hepatic Encephalopathy
  • 3.4. Cause and risk factors of Hepatic Encephalopathy
  • 3.5. Pathophysiology
  • 3.6. Pathogenesis of Hepatic Encephalopathy
  • 3.7. Diagnosis
  • 3.8. The differential diagnosis for Hepatic Encephalopathy
  • 3.9. Hepatic encephalopathy 2018: A clinical practice guideline by the Italian Association for the Study of the Liver (AISF)

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. Methodology
  • 4.3. 7MM Total Prevalent Patient Population of Hepatic Encephalopathy
  • 4.4. 7MM Total Diagnosed Prevalent Patient Population of Hepatic Encephalopathy

5. Country Wise-Epidemiology of Hepatic Encephalopathy

  • 5.1. United States Epidemiology
    • 5.1.1. Assumptions and Rationale
    • 5.1.2. Total Prevalent Cases of Hepatic Encephalopathy in the United States
    • 5.1.3. Total Diagnosed Prevalent Cases of Hepatic Encephalopathy in the United States
    • 5.1.4. Gender-Specific Diagnosed Prevalence of Hepatic Encephalopathy in the United States
    • 5.1.5. Age-Specific Diagnosed Prevalence of Hepatic Encephalopathy in the United States
    • 5.1.6. Type-Specific Diagnosed Prevalence of Hepatic Encephalopathy in the United States
  • 5.2. EU5 Epidemiology
    • 5.2.1. Germany
      • 5.2.1.1. Assumptions and Rationale
      • 5.2.1.2. Total Prevalent Cases of Hepatic Encephalopathy in Germany
      • 5.2.1.3. Total Diagnosed Prevalent Cases of Hepatic Encephalopathy in Germany
      • 5.2.1.4. Gender-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Germany
      • 5.2.1.5. Age-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Germany
      • 5.2.1.6. Type-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Germany
    • 5.2.2. France
      • 5.2.2.1. Assumptions and Rationale
      • 5.2.2.2. Total Prevalent Cases of Hepatic Encephalopathy in France
      • 5.2.2.3. Total Diagnosed Prevalent Cases of Hepatic Encephalopathy in France
      • 5.2.2.4. Gender-Specific Diagnosed Prevalence of Hepatic Encephalopathy in France
      • 5.2.2.5. Age-Specific Diagnosed Prevalence of Hepatic Encephalopathy in France
      • 5.2.2.6. Type-Specific Diagnosed Prevalence of Hepatic Encephalopathy in France
    • 5.2.3. Italy
      • 5.2.3.1. Assumptions and Rationale
      • 5.2.3.2. Total Prevalent Cases of Hepatic Encephalopathy in Italy
      • 5.2.3.3. Total Diagnosed Prevalent Cases of Hepatic Encephalopathy in Italy
      • 5.2.3.4. Gender-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Italy
      • 5.2.3.5. Age-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Italy
      • 5.2.3.6. Type-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Italy
    • 5.2.4. Spain
      • 5.2.4.1. Assumptions and Rationale
      • 5.2.4.2. Total Prevalent Cases of Hepatic Encephalopathy in Spain
      • 5.2.4.3. Total Diagnosed Prevalent Cases of Hepatic Encephalopathy in Spain
      • 5.2.4.4. Gender-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Spain
      • 5.2.4.5. Age-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Spain
      • 5.2.4.6. Type-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Spain
    • 5.2.5. United Kingdom
      • 5.2.5.1. Assumptions and Rationale
      • 5.2.5.2. Total Prevalent Cases of Hepatic Encephalopathy in the United Kingdom
      • 5.2.5.3. Total Diagnosed Prevalent Cases of Hepatic Encephalopathy in the United Kingdom
      • 5.2.5.4. Gender-Specific Diagnosed Prevalence of Hepatic Encephalopathy in the UK
      • 5.2.5.5. Age-Specific Diagnosed Prevalence of Hepatic Encephalopathy in the UK
      • 5.2.5.6. Type-Specific Diagnosed Prevalence of Hepatic Encephalopathy in the UK

6. Japan Epidemiology

  • 6.1. Assumptions and Rationale
  • 6.2. Total Prevalent Cases of Hepatic Encephalopathy in Japan
  • 6.3. Total Diagnosed Prevalent Cases of Hepatic Encephalopathy in Japan
  • 6.4. Gender-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Japan
  • 6.5. Age-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Japan
  • 6.6. Type-Specific Diagnosed Prevalence of Hepatic Encephalopathy in Japan

7. Treatment and Management of Hepatic Encephalopathy

  • 7.1. Line of therapies for the treatment of Hepatic Encephalopathy
  • 7.2. Treatment algorithm
  • 7.3. Treatment Guideline
    • 7.3.1. Practice Guideline on Hepatic Encephalopathy from the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver
    • 7.3.2. Hepatic encephalopathy 2018: A clinical practice guideline by the Italian Association for the Study of the Liver (AISF)

8. Unmet Needs

9. Marketed Drugs

  • 9.1. Xifaxan: Salix Pharmaceuticals
    • 9.1.1. Product Description
    • 9.1.2. Regulatory Milestones
    • 9.1.3. Research and Development
    • 9.1.4. Clinical Trials Information
    • 9.1.5. Product Profile

10. Emerging Drugs

  • 10.1. Key Cross Competition
  • 10.2. SYNB1020: Synlogic
    • 10.2.1. Product Description
    • 10.2.2. Other Developmental Activities
    • 10.2.3. Clinical Development
    • 10.2.4. Clinical Trials Information
    • 10.2.5. Product Profile
  • 10.3. GR3027: Umecrine Cognition
    • 10.3.1. Product Description
    • 10.3.2. Other Developmental Activities
    • 10.3.3. Clinical Development
    • 10.3.4. Safety and Efficacy
    • 10.3.5. Product Profile
  • 10.4. MNK-6105/ MNK-6106: Mallinckrodt Therapeutics
    • 10.4.1. Product Description
    • 10.4.2. Other Developmental Activities
    • 10.4.3. Clinical Development
    • 10.4.4. Clinical Trials Information
    • 10.4.5. Product Profile

11. Hepatic Encephalopathy: 7 Major Market Analysis

  • 11.1. Key Findings
  • 11.2. Market Size of Hepatic Encephalopathy in the 7MM
  • 11.3. Market Size of Hepatic Encephalopathy by Therapies in the 7MM

12. Market Outlook: The United States

  • 12.1. United States Market Size
    • 12.1.1. The total Market size of Hepatic Encephalopathy
    • 12.1.2. Hepatic Encephalopathy Market by Current Treatment & Emerging Therapy

13. Market Outlook: Europe

  • 13.1. Germany
    • 13.1.1. Total Market size of Hepatic Encephalopathy
    • 13.1.2. Hepatic Encephalopathy Market by Current Treatment & Emerging Therapy
  • 13.2. France
    • 13.2.1. Total Market size of Hepatic Encephalopathy
    • 13.2.2. Hepatic Encephalopathy Market by Current Treatment & Emerging Therapy
  • 13.3. Italy
    • 13.3.1. Total Market size of Hepatic Encephalopathy
    • 13.3.2. Hepatic Encephalopathy Market by Current Treatment & Emerging Therapy
  • 13.4. Spain
    • 13.4.1. Total Market size of Hepatic Encephalopathy
    • 13.4.2. Hepatic Encephalopathy Market by Current Treatment & Emerging Therapy
  • 13.5. United Kingdom
    • 13.5.1. Total Market size of Hepatic Encephalopathy
    • 13.5.2. Hepatic Encephalopathy Market by Current Treatment & Emerging Therapy

14. Market Outlook: Japan

  • 14.1. Total Market size of Hepatic Encephalopathy
  • 14.2. Hepatic Encephalopathy Market by Current Treatment & Emerging Therapy

15. Market Drivers

16. Market Barriers

17. Appendix

  • 17.1. Report Methodology

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

Back to Top